Cara Therapeutics/CARA

$0.76

-5.15%
-
1D1W1MYTD1YMAX

About Cara Therapeutics

Cara Therapeutics, Inc. is a development-stage biopharmaceutical company. The Company is focused on treatment paradigm to improve the lives of patients suffering from chronic pruritus. It is developing an oral formulation of difelikefalin, a selective, predominantly peripherally acting, non-scheduled Kappa opioid receptor agonist, for the treatment of chronic neuropathic pruritus associated with Notalgia Paresthetica (NP), a common, underdiagnosed neuropathy affecting the upper back. It is conducting Phase II/III Clinical Program in NP. The program is comprised of two studies - KOURAGE 1 and KOURAGE 2, which are double-blind, placebo-controlled, eight-week studies with patients allowed to roll-over into open-label 52-week extensions. It has developed an IV formulation of difelikefalin, for the treatment of moderate-to-severe pruritus associated with advanced chronic kidney disease in adults undergoing hemodialysis. The IV formulation is out-licensed worldwide.

Ticker

CARA

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Christopher Posner

Employees

55

Headquarters

Stamford, United States

CARA Metrics

BasicAdvanced
$42M
Market cap
-
P/E ratio
-$2.26
EPS
0.82
Beta
-
Dividend rate
$42M
0.81683
$4.48
$0.50
584K
5.381
5.199
-100.7%
-147.29%
-115.83%
2.453
1.394
1.394
-60.83%
-43.75%
-46.26%

What the Analysts think about CARA

Analyst Ratings

Majority rating from 5 analysts.
Buy

Price Targets

Average projection from 7 analysts.
588.16% upside
High $10.00
Low $1.00
$0.76
Current price
$5.23
Average price target

CARA Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-1,457.14% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$2.1M
-30%
Net income
-$31M
-5.26%
Profit margin
-1,457.14%
35.34%

CARA Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 40.7%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.58
-$0.52
-$0.59
-$0.56
-
Expected
-$0.54
-$0.52
-$0.41
-$0.40
-$0.28
Surprise
7.74%
0%
43.2%
40.7%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Cara Therapeutics stock?

Cara Therapeutics (CARA) has a market cap of $41M as of May 20, 2024.

What is the P/E ratio for Cara Therapeutics stock?

The price to earnings (P/E) ratio for Cara Therapeutics (CARA) stock is 0 as of May 20, 2024.

Does Cara Therapeutics stock pay dividends?

No, Cara Therapeutics (CARA) stock does not pay dividends to its shareholders as of May 20, 2024.

When is the next Cara Therapeutics dividend payment date?

Cara Therapeutics (CARA) stock does not pay dividends to its shareholders.

What is the beta indicator for Cara Therapeutics?

Cara Therapeutics (CARA) has a beta rating of 0.81. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Cara Therapeutics stock price target?

The target price for Cara Therapeutics (CARA) stock is $5.23, which is 597.33% above the current price of $0.75. This is an average based on projections from 7 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Cara Therapeutics stock

Buy or sell Cara Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing